Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS. van der Voort A, et al. Among authors: vrancken peeters mt. JAMA Oncol. 2021 Jul 1;7(7):978-984. doi: 10.1001/jamaoncol.2021.1371. JAMA Oncol. 2021. PMID: 34014249 Free PMC article. Clinical Trial.
Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.
van Ramshorst MS, Teixeira SC, Koolen BB, Pengel KE, Gilhuijs KG, Wesseling J, Rodenhuis S, Valdés Olmos RA, Rutgers EJ, Vogel WV, Sonke GS, Vrancken Peeters MT. van Ramshorst MS, et al. Among authors: vrancken peeters mt. Cancer Imaging. 2017 May 25;17(1):15. doi: 10.1186/s40644-017-0117-5. Cancer Imaging. 2017. PMID: 28545563 Free PMC article.
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG). van Ramshorst MS, et al. Among authors: vrancken peeters mt. Lancet Oncol. 2018 Dec;19(12):1630-1640. doi: 10.1016/S1470-2045(18)30570-9. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413379 Clinical Trial.
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters MTDF, Wesseling J, Lips EH, Sonke GS. Steenbruggen TG, et al. Clin Cancer Res. 2019 Aug 15;25(16):4985-4992. doi: 10.1158/1078-0432.CCR-19-0560. Epub 2019 May 10. Clin Cancer Res. 2019. PMID: 31076546
Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
Steenbruggen TG, Schaapveld M, Horlings HM, Sanders J, Hogewoning SJ, Lips EH, Vrancken Peeters MT, Kok NF, Wiersma T, Esserman L, van 't Veer LJ, Linn SC, Siesling S, Sonke GS. Steenbruggen TG, et al. Among authors: vrancken peeters mt. JNCI Cancer Spectr. 2021 Feb 4;5(3):pkab010. doi: 10.1093/jncics/pkab010. eCollection 2021 Jun. JNCI Cancer Spectr. 2021. PMID: 33977227 Free PMC article.
Survival and prognostic factors in oligometastatic breast cancer.
van Ommen-Nijhof A, Steenbruggen TG, Capel L, Vergouwen M, Vrancken Peeters MT, Wiersma TG, Sonke GS. van Ommen-Nijhof A, et al. Among authors: vrancken peeters mt. Breast. 2023 Feb;67:14-20. doi: 10.1016/j.breast.2022.12.007. Epub 2022 Dec 14. Breast. 2023. PMID: 36549169 Free PMC article.
A clinical perspective on oncoplastic breast conserving surgery.
Heeling E, van Hemert AKE, Vrancken Peeters MTFD. Heeling E, et al. Among authors: vrancken peeters mtfd. Transl Breast Cancer Res. 2023 Sep 28;4:29. doi: 10.21037/tbcr-23-40. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751480 Free PMC article. Review.
Margin assessment during breast conserving surgery using diffuse reflectance spectroscopy.
Veluponnar D, de Boer LL, Dashtbozorg B, Jong LS, Geldof F, Guimaraes MDS, Sterenborg HJCM, Vrancken-Peeters MTFD, van Duijnhoven F, Ruers T. Veluponnar D, et al. Among authors: vrancken peeters mtfd. J Biomed Opt. 2024 Apr;29(4):045006. doi: 10.1117/1.JBO.29.4.045006. Epub 2024 Apr 25. J Biomed Opt. 2024. PMID: 38665316 Free PMC article.
Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.
van Olmen JP, Jacobs CF, Bartels SAL, Loo CE, Sanders J, Vrancken Peeters MTFD, Drukker CA, van Duijnhoven FH, Kok M. van Olmen JP, et al. Among authors: vrancken peeters mtfd. Breast. 2024 Jun;75:103726. doi: 10.1016/j.breast.2024.103726. Epub 2024 Apr 5. Breast. 2024. PMID: 38599047 Free PMC article.
90 results